A Phase I Open-Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF26-104/RFASE in Patients with Advanced Solid Malignancies.

CONCLUSION: Despite having an attractive safety profile, hVEGF26-104 /RFASE was not able to elicit seroconversions against native hVEGF165 and, consequently, did not decrease circulating VEGF levels. Deficient RFASE adjuvant activity, as well as dominant immunoreactivity towards neo-epitopes, may have impeded hVEGF26-104 /RFASE's efficacy in man. PMID: 33105058 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33105058?dopt=Abstract

Source: The Oncologist - October 26, 2020 Category: Cancer & Oncology Authors: Goedegebuure RSA, Wentink MQ, van der Vliet HJ, Timmerman P, Griffioen AW, de Gruijl TD, Verheul HMW Tags: Oncologist Source Type: research